Division of Planning and Coordination CiCLE: Cyclic Innovation for Clinical Empowerment

This program aims at creating a foundation (including human resources) for a radical transformation in the way research and development is conducted in response to needs arising in clinical settings and for accelerating the practical application to pharmaceutical products. It also seeks to drive the creation of an environment that strongly promotes the fostering of open innovation in the field of medical research and development through the combined efforts of government, academia, and the private sector.

• Explanatory document on the program (as of July, 2017)

Program cost

55 billion yen
 

Overview

Activities conducted under this program are classified into three types:

（1）Improving the environment for medical R&D type

Improving the environment for the development of a collaborative foundation that contributes to R&D for the practical application of drugs, medical devices, regenerative medicine products and medical technologies as well as human resource training.

（2）R&D type

R&D geared towards the practical application of drugs, medical devices, regenerative medicine products, medical technologies with a team of companies, universities and institutes based on industry-academia collaboration or industry-industry collaboration.

（3）Practical realization development type

Practical realization development of drugs, medical devices, regenerative medicine products,medical technologies, implemented in industry-academia collaboration based on seeds (patents, etc.)

System of program management

Program Management Framework

Based on the Plan for Promotion of Medical R&D, program supervisors (“PS”) and program officers (“PO”) will be assigned to oversee the operation and effective utilization of the program to ensure that it produces fruitful results.

PS and PO should comprehend the status of the entire program and give necessary instructions and advice to promote progress. The research institutions and researchers taking part in the program are required to cooperate with the PS and PO. Based on the instructions and advice given by the PS and PO, AMED may require an implementation plan for a particular project be reviewed, changed or discontinued, or for the implementation system to be changed.

Target institutions

Institutions incorporated in Japan.

Funding and period

Type	Total funds	Period
(1) Improving the environment for medical R&D (2) R&D	100 million to 10 billion yen / project in principle (Includes general administrative expenses) (Proposals exceeding the upper limit may be considered)	Within 10 years in principle (Proposals exceeding the upper limit may be considered)
(3) Practical realization development	100 million to 5 billion yen / project in principle (Includes general administrative expenses) (Proposals exceeding the upper limit may be considered)	Within 10 years in principle (Proposals exceeding the upper limit may be considered)

Provision of funding when goal is achieved / not achieved

A performance goal is set in advance. When the goal is achieved, the total amount of funds to be paid by an institution to AMED should be repaid.
(When the goal is not achieved, part of the funding should be repaid according to the conditions.)